Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Virtual healthcare compared to hospital care for acute and post-acute illness in adults: A systematic review and meta-analysis of randomized controlled trials.British journal of clinical pharmacology · 2026Pooled it
- Inpatient-level care at home delivered by virtual wards and hospital at home: a systematic review and meta-analysis of complex interventions and their components.BMC medicine · 2024Pooled it
- Admission avoidance hospital at home.The Cochrane database of systematic reviews · 2024Pooled it
- Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.The Cochrane database of systematic reviews · 2019Pooled it
- Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.The Cochrane database of systematic reviews · 2013Pooled it
- Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.Health technology assessment (Winchester, England) · 2024Trial
- Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Remote Vital Sign Monitoring in Acutely Unwell Hospital at Home Patients: Nonrandomized Feasibility Study.JMIR formative research · 2026Article
- Hospital at home enables safe and efficient outpatient management of intensively treated acute myeloid leukemia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Home hospital as a disposition for older adults from the emergency department: Benefits and opportunities.Journal of the American College of Emergency Physicians open · 2021Article
- Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.Cancer reports (Hoboken, N.J.) · 2021Article
- Article
- Mortality and admission to intensive care units after febrile neutropenia in patients with cancer.Cancer medicine · 2020Article
- Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Admission avoidance hospital at home.The Cochrane database of systematic reviews · 2016Review
- Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer.BMC cancer · 2015Article
- Febrile neutropenia in hematologic malignancies.Current hematologic malignancy reports · 2013Review
- The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
purposeFebrile neutropenia commonly complicates cancer chemotherapy. Outpatient treatment may reduce costs and improve patient comfort but risk progression of undetected medical problems. PATIENTS AND
methodsBy using our validated algorithm, we identified medically stable inpatients admitted for febrile neutropenia (neutrophils < 500/μL) after chemotherapy and randomly assigned them to continued inpatient antibiotic therapy or early discharge to receive identical antibiotic treatment at home. Our primary outcome was the occurrence of any serious medical complication, defined as evidence of medical instability requiring urgent medical attention.
resultsWe enrolled 117 patients with 121 febrile neutropenia episodes before study termination for poor accrual. We excluded five episodes as ineligible and three because of inadequate documentation of the study outcome. Treatment groups were clinically similar, but sociodemographic imbalances occurred because of block randomization. The median presenting absolute neutrophil count was 100/μL. Hematopoietic growth factors were used in 38% of episodes. The median neutropenia duration was 4 days (range, 1 to 15 days). Five outpatients were readmitted to the hospital. Major medical complications occurred in five episodes (8%) in the hospital arm and four (9%) in the home arm (95% CI for the difference, -10% to 13%; P = .56). No study patient died. Patient-reported quality of life was similar on both arms.
conclusionWe found no evidence of adverse medical consequences from home care, despite a protocol designed to detect evidence of clinical deterioration. These results should reassure clinicians who elect to treat rigorously characterized low-risk patients with febrile neutropenia in suitable outpatient settings with appropriate surveillance for unexpected clinical deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.